PDF herunterladen
Semin Liver Dis 2002; 22(s1): 023-032
DOI: 10.1055/s-2002-35697
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Assessing Hepatitis B Virus Resistance In Vitro and Molecular Mechanisms of Nucleoside Resistance

Fabien Zoulim
  • Institut Universitaire de France, Lyon, France
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. November 2002 (online)

    Lizenzen und Reprints

ABSTRACT

The development of viral resistance to drugs can significantly reduce the efficacy of therapy for chronic hepatitis B virus (HBV) infection, slowing the rate of seroconversion, reversing previous gains in liver function and histology, and allowing disease progression. The efficacy of the nucleoside analogue lamivudine has been compromised by the development of viral resistance. Research into the mechanisms of nucleoside resistance has intensified and has included the development of new resistance assays. Resistance to lamivudine appears to be caused by the compound's structural features. Mutations are selected in HBV polymerase that can discriminate among the structural differences between lamivudine triphosphate and the natural substrate mimicked by lamivudine, dCTP, causing steric hindrance and reduced efficiency of incorporation of lamivudine but not the natural substrate. Unlike lamivudine, adefovir dipivoxil, an oral anti-HBV agent in late-stage development, has not been associated with HBV resistance, either in vitro or in vivo. One long-term clinical study has shown a lack of resistance to adefovir dipivoxil in patients treated for up to 136 weeks. In addition, adefovir dipivoxil is a nucleotide (rather than a nucleoside) analogue that exhibits no cross-resistance with lamivudine and is effective against lamivudine-resistant HBV. In one hypothesis, this lack of resistance has been attributed to the minimal flexible acyclic structure of adefovir that subverts resistance due to steric hindrance. By reducing the rate and frequency of development of drug resistance, adefovir dipivoxil and other new oral antiviral agents maximize the clinical advantages of long-term sustained viral suppression (HBV DNA reduction) to achieve lasting therapeutic benefits.

KEYWORDS

Lamivudine - adefovir dipivoxil - nucleoside analogues - nucleotide analogues - antiviral resistance

REFERENCES

  • 1 Zoulim F. Evaluation of novel strategies to combat hepatitis B virus targeting wild-type and drug-resistant mutants in experimental models.  Antivir Chem Chemother . 2001;  12(Suppl 1) 131-142
    PubMedGoogle Scholar
  • 2 Ono S K, Kato N, Shiratori Y. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.  J Clin Invest . 2001;  107 449-455
    PubMedGoogle Scholar
  • 3 Das K, Xiong X, Yang H. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).  J Virol . 2001;  75 4771-4779
    CrossrefPubMedGoogle Scholar
  • 4 Nowak M A, Bonhoeffer S, Hill A M. Viral dynamics in hepatitis B virus infection.  Proc Natl Acad Sci USA . 1996;  93 4398-4402
    CrossrefPubMedGoogle Scholar
  • 5 Tsiang M, Rooney J F, Toole J J, Gibbs C S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.  Hepatology . 1999;  29 1863-1869
    CrossrefPubMedGoogle Scholar
  • 6 Doo E, Liang T J. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.  Gastroenterology . 2001;  120 1000-1008
    PubMedGoogle Scholar
  • 7 Lewin S R, Ribeiro R M, Walters T. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.  Hepatology . 2001;  34 1012-1020
    CrossrefPubMedGoogle Scholar
  • 8 Whalley S A, Brown D, Teo C G. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler.  J Clin Microbiol . 2001;  39 1456-1459
    CrossrefPubMedGoogle Scholar
  • 9 Perrillo R, Schiff E, Yoshida E. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.  Hepatology . 2000;  32 129-134
    CrossrefPubMedGoogle Scholar
  • 10 Chang T T, Lai C L, Liaw Y F. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years (Abst).  Antivir Ther . 2000;  5(Suppl 1) 44
    PubMedGoogle Scholar
  • 11 Gutfreund K S, Williams M, George R. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.  J Hepatol . 2000;  33 469-475
    CrossrefPubMedGoogle Scholar
  • 12 Okamoto H, Imai M, Kametani M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission.  Jpn J Exp Med . 1987;  57 231-236
    PubMedGoogle Scholar
  • 13 Stuyver L J, Locarnini S A, Lok A. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.  Hepatology . 2001;  33 751-757
    CrossrefPubMedGoogle Scholar
  • 14 Delaney W E, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.  Antivir Chem Chemother . 2001;  12 1-35
    PubMedGoogle Scholar
  • 15 Delaney IV E W, Edwards R, Colledge D. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.  Antimicrob Agents Chemother . 2001;  45 1705-1713
    CrossrefPubMedGoogle Scholar
  • 16 Allen M I, Gauthier J, DesLauriers M. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine.  J Clin Microbiol . 1999;  37 3338-3347
    PubMedGoogle Scholar
  • 17 Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.  Hepatology . 1999;  30 1302-1306
    CrossrefPubMedGoogle Scholar
  • 18 Lau DT-Y, Khokhar F, Doo E. Long-term therapy of chronic hepatitis B with lamivudine.  Hepatology . 2000;  32 828-834
    CrossrefPubMedGoogle Scholar
  • 19 Zoulim F. Detection of hepatitis B virus resistance to antivirals.  J Clin Virol . 2001;  21 243-253
    CrossrefPubMedGoogle Scholar
  • 20 Aberle S W, Kletzmayr J, Watschinger B. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.  J Clin Microbiol . 2001;  39 1972-1974
    CrossrefPubMedGoogle Scholar
  • 21 Stuyver L, Van Geyt C, De Gendt S. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.  J Clin Microbiol . 2000;  38 702-707
    PubMedGoogle Scholar
  • 22 Seignères B, Pichoud C, Ahmed S S. Evolution of HBV polymenase gene sequence during famciclovir therapy for chronic hepatitis B.  J Infect Dis . 2000;  181 1221-1223
    CrossrefPubMedGoogle Scholar
  • 23 Delmas J, Schorr O, Jamard C. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.  Antimicrob Agents Chemother . 2002;  46 425-433
    CrossrefPubMedGoogle Scholar
  • 24 Seignères B, Aguesse-Germon S, Pichoud C. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.  J Hepatol . 2001;  34 114-122
    PubMedGoogle Scholar
  • 25 Fu L, Cheng Y-C. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.  Antimicrob Agents Chemother . 2000;  44 3402-3407
    CrossrefPubMedGoogle Scholar
  • 26 Lanford R E, Notvall L, Beames B. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells.  J Virol . 1995;  69 4431-4439
    PubMedGoogle Scholar
  • 27 Delaney IV E W, Westland C E, Yang H L. Cross-resistance analysis of lamivudine, adefovir, and entecavir using a cell culture model of HBV replication (Abst).  Antiviral Res . 2001;  50 A81
    PubMedGoogle Scholar
  • 28 Chin R, Shaw T, Torresi J. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil.  Antimicrob Agents Chemother . 2001;  45 2495-2501
    CrossrefPubMedGoogle Scholar
  • 29 Pichoud C, Seignères B, Wang Z. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.  Hepatology . 1999;  29 230-237
    CrossrefPubMedGoogle Scholar
  • 30 Yang H, Westland C E, Delaney W E. Lack of emerging resistance mutations in 467 HBeAg-negative and HBeAg-positive patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks. Abstracts of the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain
    Google Scholar
  • 31 Yang H, Westland C E, Delaney IV E W. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks (Abst).  Hepatology . 2001;  34 316A
    PubMedGoogle Scholar
  • 32 Heathcote E J, Jeffers L, Perrillo R. Sustained antiviral response and lack of viral resistance with long-term adefovir dipivoxil therapy in chronic hepatitis B virus infection. Abstracts of the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst 590)
    Google Scholar
  • 33 Delaney W, Yang H, Gibbs C. Lamivudine-resistant hepatitis B virus is cross-resistant to L-dT and L-dC in vitro. Abstracts of the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst 632)
    Google Scholar
  • 34 Werle B, Wursthorn K, Petersen J. Development of a quantitative assay for hepatic cccDNA levels in patients with chronic hepatitis B. Abstracts of the 37th Annual Meeting of the European Association for the Study of the Liver; April 17-21, 2002; Madrid, Spain (Abst 590)
    Google Scholar

1 *Adefovir diphosphate is the active metabolite of adefovir. Adefovir dipivoxil is the oral prodrug of adefovir [23]